Cut it out you two, patience ,in the next 3 months, interim review and EU reimbursement , why not?
Slow enrolment was expected , 21 hospitals now enrolling, implants are accelerating ,that $3 billion company has not enrolled one person in its class 3-4 trial Revive-it trial, if that device stops you're dead and the blood clotting problems ?together the FDA deems too risky for class 3 , that trial is dead in the water and it commenced before SSH's ,SSH has class 3 on its own now with a better and safer heart assist device , no other known treatment achieves what C-pulse does ,take advantage of the shorting , SSH is a screaming Buy, just 3 months is what it will take in my opinion, cheers.
- Forums
- ASX - By Stock
- SHC
- Lonestar Algisyl-LVR
Lonestar Algisyl-LVR, page-27
-
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)